insights_auto
Why is DMN down २.८१%?
Dive Deeperchevron_right
DMN:FRA
Diamyd Medical AB
€ ०.०५९
arrow_downward
-२.८१%(-०.००१७) 1D
नोभेम्बर १८, ०८:०४:५४ GMT+१ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
€ ०.०६
High
€ ०.०६
Low
€ ०.०६
Mkt. cap
१३.२४ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.८०
52-wk low
€ ०.०५
No. of employees
४२
Open
€ ०.०६
High
€ ०.०६
Low
€ ०.०६
Mkt. cap
१३.२४ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.८०
52-wk low
€ ०.०५
No. of employees
४२
News stories
From web sources and news partners
MarketWatch
·
१४ मिनेट पहिले
The S&P 500 just broke a crucial support level. Here’s what history shows may happen now.
TradingView
·
१ घण्टा पहिले
SPX: S&P 500 Futures Edge Higher After Four-Day Slide, Nvidia Earnings Buoy Tech Stocks
BigGo Finance
·
१० घण्टा पहिले
Wall Street Split on 2027 S&P 500 Outlook: Wells Fargo's 8,200 vs. Morgan Stanley's 8,700
ChartMill
·
१० घण्टा पहिले
S&P 500 After-Hours Gainers for Nov. 17, 2026
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB